To elucidate the mechanism of how hyperactivation impairs CLL progression, we again employed the genetic strategy of PI3K/AKT hyperactivation by forced constitutively active AKT1 expression in MEC-1 cells. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.